Tokyo Tape
Sign in
← Soiken Holdings

Annual report

2385.TEDINET S100WQAL
Period2024-07-01 → 2025-06-30
Filed2025-09-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 144
MetricValuePeriodScopeSource row
Revenue¥4.8bn2024-07-01 → 2025-06-30Cons.Net sales
Revenue¥5.2bn2023-07-01 → 2024-06-30Cons.Net sales
Revenue¥8.1bn2022-07-01 → 2023-06-30vCons.Net sales (5-year summary)
Revenue¥9.3bn2021-07-01 → 2022-06-30vCons.Net sales (5-year summary)
Revenue¥8.9bn2020-07-01 → 2021-06-30dCons.Net sales (5-year summary)
Operating income−¥138m2024-07-01 → 2025-06-30Cons.Operating income
Operating income−¥610m2023-07-01 → 2024-06-30Cons.Operating income
Ordinary income−¥129m2024-07-01 → 2025-06-30Cons.Ordinary income
Ordinary income−¥566m2023-07-01 → 2024-06-30Cons.Ordinary income
Ordinary income¥727m2022-07-01 → 2023-06-30vCons.Ordinary income loss (5-year summary)
Ordinary income¥1.3bn2021-07-01 → 2022-06-30vCons.Ordinary income loss (5-year summary)
Ordinary income¥920m2020-07-01 → 2021-06-30dCons.Ordinary income loss (5-year summary)
Profit before tax−¥220m2024-07-01 → 2025-06-30Cons.Income before income taxes
Profit before tax−¥615m2023-07-01 → 2024-06-30Cons.Income before income taxes
Net income (owners)−¥211m2024-07-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥662m2023-07-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥452m2022-07-01 → 2023-06-30vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥810m2021-07-01 → 2022-06-30vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥562m2020-07-01 → 2021-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥211m2024-07-01 → 2025-06-30Cons.Profit loss
Net income−¥663m2023-07-01 → 2024-06-30Cons.Profit loss
Total assets¥6.8bnat 2025-06-30Cons.Assets
Total assets¥6.9bnat 2024-06-30Cons.Assets
Total assets¥8.2bnat 2023-06-30vCons.Total assets (5-year summary)
Total assets¥8.5bnat 2022-06-30vCons.Total assets (5-year summary)
Total assets¥7.1bnat 2021-06-30dCons.Total assets (5-year summary)
Total liabilities¥775mat 2025-06-30Cons.Liabilities
Total liabilities¥697mat 2024-06-30Cons.Liabilities
Net assets / equity¥6.0bnat 2025-06-30Cons.Net assets
Net assets / equity¥6.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥7.2bnat 2023-06-30vCons.Net assets
Net assets / equity¥6.8bnat 2022-06-30vCons.Net assets (5-year summary)
Net assets / equity¥6.2bnat 2021-06-30dCons.Net assets (5-year summary)
Cash and deposits¥5.0bnat 2025-06-30Cons.Cash and deposits
Cash and deposits¥4.8bnat 2024-06-30Cons.Cash and deposits
Cash & equivalents¥5.0bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥4.8bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.9bnat 2023-06-30vCons.Cash and cash equivalents
Cash & equivalents¥6.0bnat 2022-06-30vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.3bnat 2021-06-30dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥558m2024-07-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥881m2023-07-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥102m2022-07-01 → 2023-06-30vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥107m2020-07-01 → 2021-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥389m2024-07-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14m2023-07-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥160m2022-07-01 → 2023-06-30vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥245m2021-07-01 → 2022-06-30vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2020-07-01 → 2021-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥214,0002024-07-01 → 2025-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥261m2023-07-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2022-07-01 → 2023-06-30vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥130m2021-07-01 → 2022-06-30vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥131m2020-07-01 → 2021-06-30dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-8.052024-07-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-25.322023-07-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.272022-07-01 → 2023-06-30vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.952021-07-01 → 2022-06-30vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.492020-07-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥230.22at 2025-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥238.28at 2024-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥266.41at 2023-06-30vCons.Net assets per share (5-year summary)
Net assets per share¥254.14at 2022-06-30vCons.Net assets per share (5-year summary)
Net assets per share¥230.88at 2021-06-30dCons.Net assets per share (5-year summary)
Equity ratio88.4%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.7%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio84.6%at 2023-06-30vCons.Equity to asset ratio (5-year summary)
Equity ratio78.3%at 2022-06-30vCons.Equity to asset ratio (5-year summary)
Equity ratio84.5%at 2021-06-30dCons.Equity to asset ratio (5-year summary)
ROE6.6%2022-07-01 → 2023-06-30vCons.Rate of return on equity (5-year summary)
ROE12.8%2021-07-01 → 2022-06-30vCons.Rate of return on equity (5-year summary)
ROE9.7%2020-07-01 → 2021-06-30dCons.Rate of return on equity (5-year summary)
Employees81at 2025-06-30Cons.Number of employees
Employees90at 2024-06-30Cons.Number of employees
Employees98at 2023-06-30vCons.Number of employees
Employees100at 2022-06-30vCons.Number of employees
Employees104at 2021-06-30dCons.Number of employees
Revenue¥753m2024-07-01 → 2025-06-30StandaloneNet sales
Revenue¥304m2023-07-01 → 2024-06-30StandaloneNet sales
Revenue¥377m2022-07-01 → 2023-06-30vStandaloneNet sales (5-year summary)
Revenue¥439m2021-07-01 → 2022-06-30vStandaloneNet sales (5-year summary)
Revenue¥425m2020-07-01 → 2021-06-30dStandaloneNet sales (5-year summary)
Operating income¥409m2024-07-01 → 2025-06-30StandaloneOperating income
Operating income−¥6m2023-07-01 → 2024-06-30StandaloneOperating income
Ordinary income¥420m2024-07-01 → 2025-06-30StandaloneOrdinary income
Ordinary income¥2m2023-07-01 → 2024-06-30StandaloneOrdinary income
Ordinary income¥87m2022-07-01 → 2023-06-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥137m2021-07-01 → 2022-06-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥132m2020-07-01 → 2021-06-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥388m2024-07-01 → 2025-06-30StandaloneIncome before income taxes
Profit before tax−¥9m2023-07-01 → 2024-06-30StandaloneIncome before income taxes
Net income¥448m2024-07-01 → 2025-06-30StandaloneProfit loss
Net income−¥10m2023-07-01 → 2024-06-30StandaloneProfit loss
Net income¥142m2022-07-01 → 2023-06-30vStandaloneNet income loss (5-year summary)
Net income¥195m2021-07-01 → 2022-06-30vStandaloneNet income loss (5-year summary)
Net income¥288m2020-07-01 → 2021-06-30dStandaloneNet income loss (5-year summary)
Total assets¥4.7bnat 2025-06-30StandaloneAssets
Total assets¥4.2bnat 2024-06-30StandaloneAssets
Total assets¥4.3bnat 2023-06-30vStandaloneTotal assets (5-year summary)
Total assets¥4.5bnat 2022-06-30vStandaloneTotal assets (5-year summary)
Total assets¥4.2bnat 2021-06-30dStandaloneTotal assets (5-year summary)
Total liabilities¥59mat 2025-06-30StandaloneLiabilities
Total liabilities¥29mat 2024-06-30StandaloneLiabilities
Net assets / equity¥4.6bnat 2025-06-30StandaloneNet assets
Net assets / equity¥4.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2023-06-30vStandaloneNet assets
Net assets / equity¥4.3bnat 2022-06-30vStandaloneNet assets (5-year summary)
Net assets / equity¥4.2bnat 2021-06-30dStandaloneNet assets (5-year summary)
Cash and deposits¥2.4bnat 2025-06-30StandaloneCash and deposits
Cash and deposits¥1.2bnat 2024-06-30StandaloneCash and deposits
EPS (basic)¥17.112024-07-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-0.42023-07-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥5.442022-07-01 → 2023-06-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥7.472021-07-01 → 2022-06-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.022020-07-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥52024-07-01 → 2025-06-30StandaloneDividend paid per share (5-year summary)
Dividend per share¥52022-07-01 → 2023-06-30vStandaloneDividend paid per share (5-year summary)
Dividend per share¥52021-07-01 → 2022-06-30vStandaloneDividend paid per share (5-year summary)
Dividend per share¥52020-07-01 → 2021-06-30dStandaloneDividend paid per share (5-year summary)
Net assets per share¥175.67at 2025-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥158.55at 2024-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥163.95at 2023-06-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥163.52at 2022-06-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥161.05at 2021-06-30dStandaloneNet assets per share (5-year summary)
Equity ratio98.7%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio99.3%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2023-06-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio95.6%at 2022-06-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2021-06-30dStandaloneEquity to asset ratio (5-year summary)
ROE10.2%2024-07-01 → 2025-06-30StandaloneRate of return on equity (5-year summary)
ROE3.3%2022-07-01 → 2023-06-30vStandaloneRate of return on equity (5-year summary)
ROE4.6%2021-07-01 → 2022-06-30vStandaloneRate of return on equity (5-year summary)
ROE7.0%2020-07-01 → 2021-06-30dStandaloneRate of return on equity (5-year summary)
Shares issued26,158,200at 2025-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2023-06-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2022-06-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2021-06-30dStandaloneTotal number of issued shares (5-year summary)
Employees9at 2025-06-30StandaloneNumber of employees
Employees11at 2024-06-30StandaloneNumber of employees
Employees7at 2023-06-30vStandaloneNumber of employees
Employees9at 2022-06-30vStandaloneNumber of employees
Employees8at 2021-06-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 95
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-07-01 → 2025-06-30¥548,000
Reconciling Itemsreconcilingdepreciation2024-07-01 → 2025-06-30¥557,000
Reconciling Itemsreconcilingrevenue2024-07-01 → 2025-06-30−¥26m
Reconciling Itemsreconcilingrevenue external2024-07-01 → 2025-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2024-07-01 → 2025-06-30−¥28m
Reconciling Itemsreconcilingsegment assetsat 2025-06-30¥2.8bn
Reconciling Itemsreconcilingsegment profit2024-07-01 → 2025-06-30−¥343m
Clinical Evidence Servicereportable segmentcapex2024-07-01 → 2025-06-30¥4m
Clinical Evidence Servicereportable segmentdepreciation2024-07-01 → 2025-06-30¥6m
Clinical Evidence Servicereportable segmentemployeesat 2025-06-3013 pure
Clinical Evidence Servicereportable segmentrevenue2024-07-01 → 2025-06-30¥242m
Clinical Evidence Servicereportable segmentrevenue external2024-07-01 → 2025-06-30¥242m
Clinical Evidence Servicereportable segmentsegment assetsat 2025-06-30¥321m
Clinical Evidence Servicereportable segmentsegment profit2024-07-01 → 2025-06-30¥9m
Functional Cosmetic Retailingreportable segmentcapex2024-07-01 → 2025-06-30¥30m
Functional Cosmetic Retailingreportable segmentdepreciation2024-07-01 → 2025-06-30¥2m
Functional Cosmetic Retailingreportable segmentemployeesat 2025-06-3023 pure
Functional Cosmetic Retailingreportable segmentrevenue2024-07-01 → 2025-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentrevenue external2024-07-01 → 2025-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2025-06-30¥745m
Functional Cosmetic Retailingreportable segmentsegment profit2024-07-01 → 2025-06-30¥27m
Functional Food Retailingreportable segmentcapex2024-07-01 → 2025-06-30¥357,000
Functional Food Retailingreportable segmentdepreciation2024-07-01 → 2025-06-30¥8m
Functional Food Retailingreportable segmentemployeesat 2025-06-3019 pure
Functional Food Retailingreportable segmentrevenue2024-07-01 → 2025-06-30¥2.1bn
Functional Food Retailingreportable segmentrevenue external2024-07-01 → 2025-06-30¥2.1bn
Functional Food Retailingreportable segmentrevenue intersegment2024-07-01 → 2025-06-30¥13m
Functional Food Retailingreportable segmentsegment assetsat 2025-06-30¥1.1bn
Functional Food Retailingreportable segmentsegment profit2024-07-01 → 2025-06-30¥91m
Functional Material Developmentreportable segmentdepreciation2024-07-01 → 2025-06-30¥297,000
Functional Material Developmentreportable segmentemployeesat 2025-06-306 pure
Functional Material Developmentreportable segmentrevenue2024-07-01 → 2025-06-30¥298m
Functional Material Developmentreportable segmentrevenue external2024-07-01 → 2025-06-30¥283m
Functional Material Developmentreportable segmentrevenue intersegment2024-07-01 → 2025-06-30¥15m
Functional Material Developmentreportable segmentsegment assetsat 2025-06-30¥1.3bn
Functional Material Developmentreportable segmentsegment profit2024-07-01 → 2025-06-30−¥28m
Health Care Support Servicereportable segmentcapex2024-07-01 → 2025-06-30¥3m
Health Care Support Servicereportable segmentdepreciation2024-07-01 → 2025-06-30¥1m
Health Care Support Servicereportable segmentemployeesat 2025-06-3011 pure
Health Care Support Servicereportable segmentrevenue2024-07-01 → 2025-06-30¥688m
Health Care Support Servicereportable segmentrevenue external2024-07-01 → 2025-06-30¥688m
Health Care Support Servicereportable segmentsegment assetsat 2025-06-30¥528m
Health Care Support Servicereportable segmentsegment profit2024-07-01 → 2025-06-30¥107m
—segment totalcapex2024-07-01 → 2025-06-30¥37m
—segment totaldepreciation2024-07-01 → 2025-06-30¥18m
—segment totalrevenue2024-07-01 → 2025-06-30¥4.9bn
—segment totalrevenue external2024-07-01 → 2025-06-30¥4.8bn
—segment totalrevenue intersegment2024-07-01 → 2025-06-30¥28m
—segment totalsegment assetsat 2025-06-30¥4.0bn
—segment totalsegment profit2024-07-01 → 2025-06-30¥205m
Reconciling Itemsreconcilingcapex2023-07-01 → 2024-06-30¥798,000
Reconciling Itemsreconcilingdepreciation2023-07-01 → 2024-06-30¥231,000
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-06-30−¥43m
Reconciling Itemsreconcilingrevenue external2023-07-01 → 2024-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-06-30−¥44m
Reconciling Itemsreconcilingsegment assetsat 2024-06-30¥1.4bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-06-30−¥309m
Clinical Evidence Servicereportable segmentcapex2023-07-01 → 2024-06-30¥7m
Clinical Evidence Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥5m
Clinical Evidence Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥236m
Clinical Evidence Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥221m
Clinical Evidence Servicereportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥15m
Clinical Evidence Servicereportable segmentsegment assetsat 2024-06-30¥298m
Clinical Evidence Servicereportable segmentsegment profit2023-07-01 → 2024-06-30−¥70m
Functional Cosmetic Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥6m
Functional Cosmetic Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥11m
Functional Cosmetic Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2024-06-30¥2.6bn
Functional Cosmetic Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥153m
Functional Food Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥310,000
Functional Food Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥9m
Functional Food Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥10m
Functional Food Retailingreportable segmentsegment assetsat 2024-06-30¥1.0bn
Functional Food Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥158m
Functional Material Developmentreportable segmentdepreciation2023-07-01 → 2024-06-30¥928,000
Functional Material Developmentreportable segmentrevenue2023-07-01 → 2024-06-30¥318m
Functional Material Developmentreportable segmentrevenue external2023-07-01 → 2024-06-30¥299m
Functional Material Developmentreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥19m
Functional Material Developmentreportable segmentsegment assetsat 2024-06-30¥1.3bn
Functional Material Developmentreportable segmentsegment profit2023-07-01 → 2024-06-30−¥13m
Health Care Support Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥353,000
Health Care Support Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentsegment assetsat 2024-06-30¥382m
Health Care Support Servicereportable segmentsegment profit2023-07-01 → 2024-06-30¥93m
—segment totalcapex2023-07-01 → 2024-06-30¥13m
—segment totaldepreciation2023-07-01 → 2024-06-30¥27m
—segment totalrevenue2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue external2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue intersegment2023-07-01 → 2024-06-30¥44m
—segment totalsegment assetsat 2024-06-30¥5.6bn
—segment totalsegment profit2023-07-01 → 2024-06-30−¥301m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,294
ItemContextValueUnit
Interest income noiCurrentYearDuration_NonConsolidatedMember9783000JPY
Other noiPrior1YearDuration_NonConsolidatedMember695000JPY
Other noiCurrentYearDuration_NonConsolidatedMember821000JPY
Non operating incomePrior1YearDuration_NonConsolidatedMember14558000JPY
Non operating incomeCurrentYearDuration_NonConsolidatedMember10604000JPY
Provision of allowance for doubtful accounts noePrior1YearDuration_NonConsolidatedMember6709000JPY
Provision of allowance for doubtful accounts noeCurrentYearDuration_NonConsolidatedMember－JPY
Non operating expensesPrior1YearDuration_NonConsolidatedMember6709000JPY
Non operating expensesCurrentYearDuration_NonConsolidatedMember－JPY
Ordinary incomePrior1YearDuration_NonConsolidatedMember1768000JPY
Ordinary incomeCurrentYearDuration_NonConsolidatedMember419844000JPY
Loss on valuation of stocks of subsidiaries and affiliates elPrior1YearDuration_NonConsolidatedMember9272000JPY
Loss on valuation of stocks of subsidiaries and affiliates elCurrentYearDuration_NonConsolidatedMember5114000JPY
Bad debts written off elPrior1YearDuration_NonConsolidatedMember1012000JPY
Bad debts written off elCurrentYearDuration_NonConsolidatedMember－JPY
Loss on business office resolution elPrior1YearDuration_NonConsolidatedMember－JPY
Loss on business office resolution elCurrentYearDuration_NonConsolidatedMember16788000JPY
Other elPrior1YearDuration_NonConsolidatedMember－JPY
Other elCurrentYearDuration_NonConsolidatedMember9464000JPY
Extraordinary lossPrior1YearDuration_NonConsolidatedMember10284000JPY
Extraordinary lossCurrentYearDuration_NonConsolidatedMember31366000JPY
Income before income taxesPrior1YearDuration_NonConsolidatedMember-8516000JPY
Income before income taxesCurrentYearDuration_NonConsolidatedMember388478000JPY
Income taxes currentPrior1YearDuration_NonConsolidatedMember1572000JPY
Income taxes currentCurrentYearDuration_NonConsolidatedMember-41678000JPY
Income taxes deferredPrior1YearDuration_NonConsolidatedMember367000JPY
Income taxes deferredCurrentYearDuration_NonConsolidatedMember-17440000JPY
Income taxesPrior1YearDuration_NonConsolidatedMember1939000JPY
Income taxesCurrentYearDuration_NonConsolidatedMember-59118000JPY
Profit lossPrior1YearDuration_NonConsolidatedMember-10455000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember447596000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_CapitalStockMember1836587000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_LegalCapitalSurplusMember1931477000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_CapitalSurplusMember1931477000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_GeneralReserveMember10000000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_RetainedEarningsBroughtForwardMember510684000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_RetainedEarningsMember520684000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_TreasuryStockMember－JPY
Dividends from surplusPrior1YearDuration_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-130791000JPY
Dividends from surplusPrior1YearDuration_NonConsolidatedMember_RetainedEarningsMember-130791000JPY
Profit lossPrior1YearDuration_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-10455000JPY
Profit lossPrior1YearDuration_NonConsolidatedMember_RetainedEarningsMember-10455000JPY
Purchase of treasury stockPrior1YearDuration_NonConsolidatedMember_TreasuryStockMember-0JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_CapitalStockMember－JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_LegalCapitalSurplusMember－JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_CapitalSurplusMember－JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_GeneralReserveMember－JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-141246000JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_RetainedEarningsMember-141246000JPY
Total changes of items during the periodPrior1YearDuration_NonConsolidatedMember_TreasuryStockMember-0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-06-30pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
balance sheet identitynon_consolidated 2024-06-30pass
balance sheet identitynon_consolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net assetsnon_consolidated 2023-06-30pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · net assetsnon_consolidated 2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-07-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2024-07-01/2025-06-30pass
statement vs summary · revenueconsolidated 2023-07-01/2024-06-30pass
statement vs summary · revenueconsolidated 2024-07-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2023-07-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2024-07-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-06-30pass
statement vs summary · total assetsconsolidated 2025-06-30pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass
statement vs summary · total assetsnon_consolidated 2025-06-30pass